CClinicalTrials.gg
CompletedNCT06358326Updated Sep 3, 2025

Dry Needling and Rehabilitatin Carpal Tunnel Syndrome

An interventional study of Dry needling and Control group in Dry Needling, Carpal Tunnel Syndrome and Myofacial Pain, sponsored by Karabuk University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Karabuk University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Dry needling is used for myofascial release. However, its effectiveness in carpal tunnel syndrome (CTS) is not well known. It is thought that dry needling may also be an effective treatment for CTS by providing relaxation in the fascial tissue. Therefore, this study will examine the effects of dry needling treatment on pain, function, range of motion, proprioception and disability in patients with CTS.

Read the detailed description

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy in the society, which develops due to compression of the median nerve in the carpal tunnel. With the compression of the median nerve, a pain, numbness and tingling sensation spreading to the hand and wrist affects daily living activities and reduces the quality of life. Thickening and myofascial restriction in the carpal tunnel area also contribute to this situation. For this reason, various treatment methods have been developed for CTS, ranging from conservative treatment to surgery. Dry needling is also an alternative treatment method that can be used for CTS. Dry needling allows the fascial tissue to loosen and re-enter the healing process, leading to a decrease in pain and an increase in quality of life. However, its effectiveness in patients with CTS is unknown. This study aimed to examine the effectiveness of dry needling in patients with CTS.

02

Conditions studied

  • Dry Needling
  • Carpal Tunnel Syndrome
  • Myofacial Pain
03

In context

Carpal Tunnel Syndrome

589 studies on the registry are indexed under Carpal Tunnel Syndrome; 139 are open to participants now.

This study's enrollment of 78 is above the median of 60 across 445 interventional studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Karabuk University is the lead sponsor of 126 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Volunteering to participate in the study.
  2. Being between the ages of 18-65.
  3. Being diagnosed with mild or moderate stage CTS as a result of the electroneurophysiological test.

Exclusion criteria

Exclusion Criteria:

  1. Having additional neurological, rheumatological and orthopedic disorders.
  2. Having had previous hand surgery.
  3. Having an additional acute neck, shoulder, elbow and hand problem.
  4. Having a BMI of 40 kg/m2 and above.
  5. Being pregnant.
  6. As a result of the electroneurophysiological test, the data related to the median nerve are at a severe level.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Treatment Group

    In addition to the exercise given to the control group, the treatment group will receive dry needling in the carpal tunnel area, 2 days a week for 3 weeks, for a total of 5 sessions.

    Other: Dry needling

  • Active comparator
    Control Group

    The control group will be taught and asked to perform stretching, nerve mobilization and tendon-shifting exercises for 3 weeks.

    Other: Control group

Interventions

  • OtherDry needling

    In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.

  • OtherControl group

    The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.

06

What researchers measure

Primary outcomes

  1. Pain severity

    It will be evaluated with the Visual Analogue Scale. The scale ranges from 1 to 10 at 10 mm intervals. 0 indicates absence of pain and the highest value of 10 indicates extreme pain.

    Time frame: Baseline and 3 weeks post-intervention

  2. Wrist range of motion

    Wrist flexion, extension, ulnar deviation and radial deviation joint range degrees will be measured using a universal goniometer.

    Time frame: Baseline and 3 weeks post-intervention

  3. Position sense

    In the evaluation of joint position sense (proprioception), wrist extension, elbow flexion and shoulder flexion movements will be evaluated with an inclinometer. An increase in deviation from the target angle indicates a worsening of position sense.

    Time frame: Baseline and 3 weeks post-intervention

  4. Severity of symptoms

    The patients' CTS-related symptom severity and functional status will be evaluated with the Boston Carpal Tunnel Syndrome Questionnaire. The severity of the patient's strain is scored between 1-5. Higher scores indicate greater disability.

    Time frame: Baseline and 3 weeks post-intervention

  5. Hands activity level

    Duruöz hand index will be used to evaluate hand-related activity limitations. The survey yields a total score of 0-90, with a higher score indicating greater activity restriction.

    Time frame: Baseline and 3 weeks post-intervention

  6. Nerve cross-sectional area

    With ultrasonography, the doctor will measure the median nerve cross-sectional area of the individual and the distance between the median nerve flexor retinaculum.

    Time frame: Baseline and 3 weeks post-intervention

07

Study locations

1 site
  • Pursaklar State Hospital
    Ankara, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06358326
Lead sponsor
Karabuk University
Responsible party
Musa Güneş (Principal Investigator, Karabuk University) — Principal investigator
First posted
Apr 10, 2024
Start date
Apr 5, 2024
Primary completion
Aug 30, 2024
Completion
Nov 30, 2024
Last update
Sep 3, 2025

Study contacts

Fidan Yılmaz, MsC
principal investigator · Pursaklar State Hospital
Emime EMİRMAHMUTOĞLU, Bachelors
principal investigator · Pursaklar State Hospital
Banu Gökçen BAYDOĞAN TAN, MD
study director · Pursaklar State Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion